Related Experiment Video
Updated: Jun 3, 2025
Neurogenesis Using P19 Embryonal Carcinoma Cells
Published on: April 27, 2019
Central Nervous System Tumor-Embryonal Tumors Type With Neuroendocrine Differentiation
Abstract:
The central nervous system (CNS) tumor with embryonal tumors type is a rare type of CNS tumor with lack of unifying genetic alterations or diagnostic markers. The CNS tumor-embryonal tumors (CETs) have limited therapeutic options with high probability of adverse events associated with conventional treatment. Identification of somatostatin receptor expression and/or prostate-specific membrane antigen expression in CET patients by using PET/CT imaging may be helpful for deciding therapeutic approaches in these patients as theranostics. We present a 56-year-old woman who complained of headache, diminution of vision, and diagnosed CET and demonstrated high SSTR expression on PET/CT imaging, indicating peptide receptor radionuclide therapy could be effective therapeutic option in this case.
Insights
Central nervous system embryonal tumors (CETs) lack clear markers, limiting treatment. PET/CT imaging identified somatostatin receptor (SSTR) expression in a CET patient, suggesting peptide receptor radionuclide therapy as a viable option.
Area of Science:
- Neuro-oncology
- Nuclear Medicine
- Radiology
Background:
- Central nervous system embryonal tumors (CETs) are rare, lacking specific genetic markers and effective treatments.
- Conventional therapies for CETs often lead to significant adverse events.
- Theranostic approaches using molecular imaging could personalize CET treatment.
Purpose of the Study:
- To investigate the potential of PET/CT imaging for identifying targetable receptor expression in CET patients.
- To evaluate the utility of somatostatin receptor (SSTR) and prostate-specific membrane antigen (PSMA) expression for guiding therapy.
- To present a case study illustrating the application of theranostics in CET management.
Main Methods:
- Utilized Positron Emission Tomography/Computed Tomography (PET/CT) imaging.
- Assessed expression levels of somatostatin receptors (SSTRs) and prostate-specific membrane antigen (PSMA).
- Correlated imaging findings with clinical diagnosis and potential therapeutic strategies.
Main Results:
- A 56-year-old female patient diagnosed with CET presented with headache and vision loss.
- PET/CT imaging revealed high SSTR expression in the patient's CET.
- This finding indicated a potential for peptide receptor radionuclide therapy (PRRT).
Conclusions:
- PET/CT imaging can identify specific receptor expression in CETs.
- High SSTR expression suggests PRRT as a promising theranostic option for select CET patients.
- Theranostics offer a personalized approach to managing rare CNS tumors like CETs.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
07:43An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery
Published on: August 23, 2016
